Altimmune's Upcoming Investor Conference Participation
Altimmune, Inc. (NASDAQ: ALT), a leading late clinical-stage biopharmaceutical company, is preparing to take part in two significant investor conferences. This involvement underscores Altimmune's commitment to advancing its innovative peptide-based therapeutics aimed at treating liver and cardiometabolic diseases.
Details of the Conferences
The management team at Altimmune will be available for one-on-one meetings during these events, which will provide insights into their ongoing projects and strategic direction.
Stifel 2025 Healthcare Conference
The first conference will be the Stifel 2025 Healthcare Conference. It is set for Wednesday and features a Fireside Chat beginning at 10:00 a.m. ET. This format allows for an interactive discussion, offering investors an opportunity to delve deeper into Altimmune’s breakthroughs in the biopharmaceutical sector.
Jefferies Global Healthcare Conference
The second event, the Jefferies Global Healthcare Conference, takes place Thursday with a Fireside Chat at 9:30 a.m. GMT. This provides an excellent platform for Altimmune to connect with potential investors and share updates on their extensive research and development efforts.
Webcast Availability
Both sessions will be available via webcast, enabling a wider audience to access the information shared during these pivotal discussions. Interested parties can find detailed information in the Events section of Altimmune’s official website.
About Altimmune, Inc.
At the forefront of the biopharmaceutical industry, Altimmune is engaged in the development of novel peptide-based therapeutics. Their flagship candidate, pemvidutide, is a dual receptor agonist targeting glucagon/GLP-1 for treating metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and related liver diseases. The progress of these projects holds promise for patients facing these impactful health challenges.
Ongoing Commitment to Innovation
Altimmune's innovative approach exemplifies the evolving nature of biopharmaceutical therapies. By focusing on peptide-based treatments, the company is positioned to address significant unmet medical needs. Their commitment extends not only to discovery but also to building strong relationships within the investment community.
Investor Relations
For those interested in learning more about Altimmune’s strategies and pipeline, their investor relations materials provide comprehensive insights. The company's leadership is dedicated to transparency and open communication, recognizing the importance of keeping stakeholders informed.
Media Engagement
Furthermore, Altimmune encourages direct communication with its media contact for inquiries related to press information and company updates. Keeping the lines of communication open is essential for maintaining trust and engagement with the public and potential investors.
Frequently Asked Questions
What is Altimmune, Inc. involved in?
Altimmune is a biopharmaceutical company focused on creating innovative therapies for liver and cardiometabolic diseases.
What conferences is Altimmune participating in?
Altimmune will be featured at the Stifel 2025 Healthcare Conference and the Jefferies Global Healthcare Conference.
How can I access the conference webcasts?
The webcasts will be accessible via the Events section of Altimmune’s official website.
What is pemvidutide?
Pemvidutide is Altimmune’s leading product candidate, targeting metabolic dysfunction and related liver diseases.
How can I contact Altimmune for more information?
For more inquiries, you can reach out to their investor or media contacts available on their website.
